Abstract BACKGROUND Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy
Abstract Recent studies have identified a previously uncharacterized protein C11orf53 (now named POU2AF2/OCA-T1), which functions as a robust co-activator of POU2F3, the master transcription factor
Abstract Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12
Editor’s summary Acquired drug resistance to certain targeted cancer therapies can lead to histological transformation (HT) from one tumor type to a more aggressive type.
Abstract Myeloid cells are known to suppress antitumour immunity1. However, the molecular drivers of immunosuppressive myeloid cell states are not well defined. Here we used
Abstract Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. The prognosis of patients with metastatic cSCC is poor emphasizing the need
Abstract Brain metastases represent an important clinical problem for patients with small-cell lung cancer (SCLC). However, the mechanisms underlying SCLC growth in the brain remain
Abstract Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry TSC1/TSC2 mutations, causing mTORC1 hyperactivation and uncontrolled cell growth. mTORC1 inhibitors
Abstract Mitochondria are critical to the governance of metabolism and bioenergetics in cancer cells1. The mitochondria form highly organized networks, in which their outer and
Abstract Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell
Highlights Summary Local environmental factors influence CD8+ T cell priming in lymph nodes (LNs). Here, we sought to understand how factors unique to the tumor-draining mediastinal LN
Abstract Studies to date have not resolved how diverse transcriptional programs contribute to the intratumoral heterogeneity of small cell lung carcinoma (SCLC), an aggressive tumor
Lung cancer is the leading cause of cancer death among both men and women in the United States, making up almost 25% of all cancer
Highlights •Unsupervised clustering revealed subtype with EMT and phosphoprotein signatures •Potential therapeutic vulnerabilities included survivin, NSD3, LSD1, and EZH2 •Rb phosphorylation nominated as a biomarker
Abstract Macrophages have a key role in shaping the tumour microenvironment (TME), tumour immunity and response to immunotherapy, which makes them an important target for
Abstract Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways
Bottom Line: Among patients with lung cancer from Latin America, genomic and ancestry analyses revealed that Native American ancestry was associated with increased mutations in
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects
A collaboration between software engineers and clinical researchers has produced an artificial intelligence program that uses images to predict with 94 percent accuracy which people
Synthetic lethality results when mutant KRAS and EGFR proteins are co-expressed in human lung adenocarcinoma (LUAD) cells, revealing the biological basis for mutual exclusivity of
Highlights •High TMB correlates with efficacy of PD-1 plus CTLA-4 blockade in NSCLC •TMB and PD-L1 are independent variables •In multivariate analysis, TMB associated most
Highlights •A chemistry-first approach for druggable target identification for lung cancer •Mapping the associations between chemicals and genetic lesions in lung cancer •Matching chemicals with
Treating an aggressive type of lung cancer with a combination of immunotherapy and chemotherapy significantly improves patients’ survival compared with chemotherapy alone, according to a
By now, if you aren’t aware of the association between smoking and lung cancer, then it is possible you may have just awoken from some
Cigarette smoke contributes to epigenetic and genetic changes in lung cancer. But whether and how these alterations interact in lung cancer initiation has remained unclear.
Created by ePubSystems. Contact Us for similar site for your university or institute.